Who Paid My Doc
Shane Thomas
General Practice Kansas City, KS Doctor of Osteopathy
NPI 1407134034 CMS profile 3607640
3901 Rainbow Blvd Psychiatry And Behavioral Sciences, Kansas City, KS 66160
General payments
$163
Research payments
$0
Ownership & investment interest
$0
Through program year 2024, Shane Thomas of Kansas City, KS is reported in the CMS Open Payments database as having received $163 across 3 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 46th percentile of General Practice profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
2 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2024 | General | $124 | 1 | |
| 2019 | General | $40 | 2 |
Beside peers
- Shane Thomas
- General Practice median
- Middle half of General Practice
- National median
In program year 2025, general payments to Shane Thomas were reported at $0. Among 4,774 General Practice profiles paid that year, the median was $106 and the middle half received between $35 and $292.
Show as a table
| Year | Shane Thomas | General Practice median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $40 | $107 | $37–$285 | $163 |
| 2020 | $0 | $75 | $25–$213 | $114 |
| 2021 | $0 | $93 | $30–$272 | $132 |
| 2022 | $0 | $103 | $36–$279 | $149 |
| 2023 | $0 | $106 | $34–$276 | $160 |
| 2024 | $124 | $114 | $39–$290 | $164 |
| 2025 | $0 | $106 | $35–$292 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 12 drugsPart D claims
266
Drug cost
$3,524
Branded share of claims
10.9%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Duloxetine Hcl | Generic | 24 | $543 | |
| Prazosin Hcl | Generic | 13 | $462 | |
| Risperidone | Generic | 23 | $425 | |
| Buspirone Hcl | Generic | 26 | $414 | |
| Bupropion Xl Bupropion Hcl | Brand | 11 | $299 | |
| Trazodone Hcl | Generic | 26 | $293 | |
| Propranolol Hcl | Generic | 14 | $293 | |
| Alprazolam | Generic | 39 | $238 | |
| Clonazepam | Generic | 30 | $189 | |
| Mirtazapine | Generic | 21 | $167 |
The 10 drugs with the highest cost, of 12 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.
Records
3 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
General Practice in Kansas
Practitioners in the same specialty and state, ranked by reported value.
All General Practice
Everyone recorded under this specialty, nationwide.
Doctors in Kansas
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.